<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">The ferroquine compound FQ (SSR97193) is a successful representative of an organometallic drug (Sharma 
 <xref ref-type="bibr" rid="CR83">2005</xref>; Biot et al. 
 <xref ref-type="bibr" rid="CR13">2011</xref>). Because of its good antimalarial activity, it has been the object of many studies (Barends et al. 
 <xref ref-type="bibr" rid="CR8">2007</xref>; Biot et al. 
 <xref ref-type="bibr" rid="CR13">2011</xref>; Wani et al. 
 <xref ref-type="bibr" rid="CR91">2015</xref>) and is now the only metal-based compound that is in phase II clinical test for malaria therapy. Daher et al. (
 <xref ref-type="bibr" rid="CR28">2006</xref>) reported in vitro studies on the metabolism of ferroquine (SSR97193) in animals and humans, indicating potential applications of ferroquine in malaria therapy.
</p>
